U.S. FDA rejects wider use of Xarelto drug

[Reuters] – U.S. health regulators have declined to approve proposed wider uses of Bayer AG and Johnson & Johnson’s lucrative blood clot preventer Xarelto, the drugmakers said on Friday. The companies had sought approval from the U.S. Food and Drug Admin more

View todays social media effects on JNJ

View the latest stocks trending across Twitter. Click to view dashboard

See who Johnson is hiring next, click here to view